Development of recalcitrant cutaneous eruptions in patients with relapsed/refractory Hodgkin's lymphoma undergoing treatment with camidanlumab tesirine. J Eur Acad Dermatol Venereol 2023 Jul;37(7):e890-e893
Date
02/18/2023Pubmed ID
36800311DOI
10.1111/jdv.18983Scopus ID
2-s2.0-85149399595 (requires institutional sign-in at Scopus site)Author List
Himed S, Chung C, Dulmage B, Jaglowski S, Bond D, Maddocks K, Kaffenberger BHAuthor
Samantha M. Jaglowski MD, MPH Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antineoplastic AgentsAntineoplastic Combined Chemotherapy Protocols
Hodgkin Disease
Humans
Immunoconjugates
Neoplasm Recurrence, Local
Recurrence
Treatment Outcome
